Trovagene, Novartis deal

Trovagene granted Novartis' Genoptix Inc. a worldwide, non-exclusive license to use nucelophosmin ( NPM1; B23) in research and clinical testing for acute myelogenous leukemia (AML). Trovagene said NP...